Medtronic Inc. (NYSE:MDT) released another version of its Activa deep-brain stimulation device for the treatment of Parkinson’s disease.
The Fridley, Minn.-based medical device giant said the Activa SC will fit into its current suite of Activa DBS products, which help calm tremors in patients suffering from the neurological disorder that affects an estimated four to six million individuals across the globe, according to the National Parkinson’s Foundation.
Sales of the devices helped boost Medronic’s neuromodulation business by 2 percent during the three months ended Jan. 28 and 1 percent for the year to date.
Total sales for the unit amounted to $401 million for the third quarter and $1.15 billion for the nine-month period, according to regulatory filings.
“More than 15 years since Medtronic DBS Therapy was first introduced, it remains one of the most innovative therapies available for movement disorders,” Tom Tefft, president of the neuromodulation business, said in prepared remarks. “We are proud to continue to lead the way in the development of new DBS indications and device innovations — including Activa SC — to improve the management of patients and the outcomes of their DBS therapy.”
The company says it has implanted DBS devices in more than 80,000 patients across the globe.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.